To evaluate the impact of the Society for Gynecologic Oncology (SGO) statement on genetic testing (GT) on referral and acceptance of GT in epithelial ovarian cancer (EOC), fallopian tube cancer (FTC) and peritoneal cancer (PC).METHODS:
Retrospective cohort study comparing women newly diagnosed with EOC, FTC and PC in the year prior to and following the availability of the SGO statement to providers at a single institution on April 1, 2014.RESULTS:
Eighty-nine patients met eligibility criteria and 72 were included in the final analysis. Eight patients were excluded because they had only 1–2 visits with physicians and 9 had documented GT prior to first consultation. Included patients were diagnosed with EOC (n=56), FTC (n=12) or PC (n=4) between April 1, 2013 and March 31, 2015. Mean age was 62.79 (±12.01) and BMI 28.22 (±6.95). Referral for GT was made to 54 (75%) and 43 (60%) completed testing. Thirty-seven were diagnosed prior to availability of the statement and 35 after. Forty-three (79.6%) referrals across both groups were made after the statement issue and there was significantly less time from initial consultation to GT (343.9 vs 211.3 days; t(37)=1.69, P=.013) and from referral to GT (190.0 vs 105.1 day; t(37)=1.69, P=.029). Of those tested, 12 (23.1%) had a genetic mutation including BRCA 1, BRCA2 and MSH6 gene mutations.CONCLUSION:
SGO position statement advising that all women diagnosed with EOC, FTC and PC should receive GT increased physician referral rate and decreased delay in referral and acceptance of GT.